NT-proBNP与CVP对蒽环类药物致心脏毒性的早期监测应用的临床意义

The clinical significance of early monitoring of NT-proBNP and CVP of anthracycline-induced cardiotoxicity

目的:探讨N末端原脑利钠肽前体(NT-proBNP)与中心静脉压(CVP)对蒽环类药物所致心脏毒性的早期监测及其临床意义。方法:对我院乳腺癌术后应用蒽环类化疗药物化疗的女性患者80例,在化疗前、第1、2、3个疗程结束及全程化疗结束后5个时间点,使用免疫荧光法定量测定患者血浆NT-proBNP浓度,同时对患者行深静脉穿刺置管CVP测定并记录结果。结果:NT-proBNP在第1、2、3个疗程结束及全程化疗结束时其水平与化疗前比较均有统计学意义(均P<0.05),CVP在化疗结束时与化疗前比较有统计学意义(P<0.05)。结论:NT-proBNP联合CVP对在乳腺癌患者中应用蒽环类药物化疗致心脏毒性的早期监测有必要,加强其检测可对保护心脏功能以及判断预后有重要意义。

Objective:To investigate the NT-proBNP and CVP monitoring and clinical significance of early cardi-ac anthracycline-induced toxicity.Methods:All 80 female breast cancer patients in our hospital treated by anthracy-cline chemotherapy were tested at five time-points:before chemotherapy,end of first treatment,end of first two cour-ses,end of first three courses,end of all courses by using NT-proBNP and CVP measurements.Results:The levels of NT-proBNP at the end of first treatment,end of first two courses,end of first three courses,end of all courses were significantly increased(all P<0.05 ),compared with before chemotherapy,the levels of CVP were only significantly increased at the end of chemotherapy(P<0.05).Conclusion:NT-proBNP and CVP can be applied to monitor an-thracycline chemotherapy-induced cardiotoxicity.